Plain-English translation of NCT04464759 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing whether — a medication that affects how cells recycle their contents — can make immunotherapy drugs like work better against advanced melanoma. Researchers believe this combination might help the body's immune system fight the cancer more effectively. The trial has multiple phases to first find the safest doses, then test whether the treatment actually shrinks tumors.
While immunotherapy has helped many melanoma patients, not everyone responds well to it, and some cancers become resistant over time. This trial is exploring whether this medication can unlock the immune system's ability to attack melanoma more powerfully.
You would take by mouth twice daily and receive intravenous infusions of immunotherapy every 3–4 weeks (the schedule depends on which combination you are assigned). The trial lasts up to 24 months, continuing as long as the treatment is working and you are tolerating it well. You would have regular visits for blood tests, imaging scans, and check-ins to monitor how you are responding and watch for side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States